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OBJECTIVE—In mice, haploinsufﬁciency of the IGF-1 receptor
(IGF-1R+/2), at a whole-body level, increases resistance to inﬂam-
mation and oxidative stress, but the underlying mechanisms
are unclear. We hypothesized that by forming insulin-resistant
heterodimers composed of one IGF-1Rab and one insulin recep-
tor (IR), IRab complex in endothelial cells (ECs), IGF-1R reduces
free IR, which reduces EC insulin sensitivity and generation of
the antioxidant/anti-inﬂammatory signaling radical nitric oxide
(NO).
RESEARCH DESIGN AND METHODS—Using a number of
complementary gene-modiﬁed mice with reduced IGF-1R at
a whole-body level and speciﬁcally in EC, and complementary
studies in EC in vitro, we examined the effect of changing IGF-
1R/IR stoichiometry on EC insulin sensitivity and NO bioavail-
ability.
RESULTS—IGF-1R+/2 mice had enhanced insulin-mediated glu-
cose lowering. Aortas from these mice were hypocontractile to
phenylephrine (PE) and had increased basal NO generation and
augmented insulin-mediated NO release from EC. To dissect EC
from whole-body effects we generated mice with EC-speciﬁc
knockdown of IGF-1R. Aortas from these mice were also hypo-
contractile to PE and had increased basal NO generation.
Whole-body and EC deletion of IGF-1R reduced hybrid receptor
formation. By reducing IGF-1R in IR-haploinsufﬁcient mice we re-
duced hybrid formation, restored insulin-mediated vasorelaxation
in aorta, and insulin stimulated NO release in EC. Complemen-
tary studies in human umbilical vein EC in which IGF-1R was
reduced using siRNA conﬁrmed that reducing IGF-1R has favor-
able effects on NO bioavailability and EC insulin sensitivity.
CONCLUSIONS—These data demonstrate that IGF-1R is a crit-
ical negative regulator of insulin sensitivity and NO bioavailability
in the endothelium. Diabetes 60:2169–2178, 2011
Type 2 diabetes is a major cause of arterial ath-erosclerosis, leading to premature myocardialinfarction (1), stroke (2), and peripheral vasculardisease (3). A key feature of type 2 diabetes is
insulin resistance, which is manifest by an inability of insulin
to activate its complex signaling network in an appro-
priate temporospatial fashion (4). Recently it has emerged
that in addition to its classic target tissues (muscle, liver,
and fat), insulin resistance affects multiple cell types, in-
cluding the vascular endothelium (5).
We have demonstrated that insulin resistance at a whole-
body level (6,7), and speciﬁc to the endothelium (8), leads to
reduced bioavailability of the anti-inﬂammatory/antioxidant,
vasoactive signaling radical nitric oxide (NO), indicative of
a critical role for insulin in regulating NO bioavailability.
Consistent with this paradigm, a number of studies support
an independent role for insulin resistance in the devel-
opment of cardiovascular atherosclerosis and its compli-
cations (e.g., 9).
The IGF-1 receptor (IGF-1R) and insulin receptor (IR)
are very similar tetrameric glycoproteins composed of two
extracellular a and two transmembrane b subunits, linked
by disulphide bonds (10). Because of this high homology,
IGF-1R and IR can heterodimerize to form hybrid recep-
tors composed of one IGF-1Rab complex and one IRab
subunit complex (11,12). These hybrids have been shown
to bind IGF-1, but not insulin, with high afﬁnity (13). Hy-
brid receptors are more common in insulin-resistant indi-
viduals with type 2 diabetes and correlate with insulin
sensitivity (14). In endothelial cells (ECs), IGF-1Rs sub-
stantially outnumber IRs (15), raising the possibility that
IGF-1R may be a negative regulator of insulin signaling in
the endothelium.
To explore this hypothesis and dissect the effect of
manipulating IGF-1R numbers in the endothelium, we used
four different gene-modiﬁed mice: 1) mice with whole-body
haploinsufﬁciency of IGF-1R, 2) mice with different
degrees of deletion of IGF-1R speciﬁc to the endothelium,
and 3) mice with haploinsufﬁciency of IGF-1R IR at a
whole-body level. These complementary models under-
pinned by in vitro studies support a novel mechanism by
which IGF-1R is a critical negative regulator of insulin
sensitivity and NO bioavailability in the EC.
RESEARCH DESIGN AND METHODS
Gene-modiﬁed mice. We used four different gene-modiﬁed mice to examine
the role of IGF-1R in EC insulin sensitivity and NO production. All mice were
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bred onto a C57BL/6J background to at least 10 generations in a conventional
animal facility with a 12-h light/dark cycle. Male mice aged 3 months were used.
All experiments were conducted in accordance with accepted standards of
humane animal care under U.K. Home Ofﬁce Project license no. 40/2988.
Mice with whole-body haploinsufﬁciency of IGF-1R.Mice with whole-body
haploinsufﬁciency of IGF-1R (16) were obtained from The European Mutant
Mouse Archive (Munich, Germany; http://www.emmanet.org) and maintained in
the heterozygous state on a C57BL/6J background by mating IGF-1R+/2 males
with 9–12-week-old C57BL/6J female wild-type mice.
Mice with haploinsufﬁciency of both IGF-1R and IR. To examine the effect
of changing IGF-1R:IR stoichiometry on endothelial responses, we bred male
IGF-1R+/2 mice with female IR+/2 mice to generate mice with whole-body
haploinsufﬁciency of IR and IGF-1R (IR+/2/IGF-1R+/2).
Mice with endothelium-speciﬁc deletion of IGF-1R. To generate mice with
endothelium-speciﬁc deﬁciency of IGF-1R, we used mice carrying a ﬂoxed
IGF-1R allele (IGF-1RLox), as previously described (17), and mice expressing
the cre recombinase under control of the Tie2 promoter (Tie-2 cre; Jackson
Laboratories, Bar Harbor, ME). A mating program of male Tie-2-cre mice (to
avoid the possibility of inheritance of a null allele in the second generation,
which is not tissue speciﬁc) with female IGF-1RLox was used. Male heterozygous
and homozygous Tie-2-cre/IGF-1RLox mice were compared with age-matched
littermate controls.
Metabolic tests.Blood was sampled from tail vein. Glucose, insulin, and IGF-1
tolerance tests were performed by blood sampling after an intraperitoneal
injection of glucose (1 mg/g; Sigma-Aldrich, Dorset, U.K.), human recombinant
insulin (0.75 units/kg, Actrapid; Novo Nordisk, Bagsvaerd, Denmark), or human
recombinant IGF-1 (0.75 mg/g; GroPep, Adelaide, Australia), as previously
described (18). Glucose concentrations were determined in whole blood by a
portable meter (Roche Diagnostics, West Sussex, U.K.). Plasma insulin con-
centrations were determined by enzyme-linked immunoassay (Ultrasensitive
mouse ELISA; CrystalChem, Downers Grove, IL). Plasma IGF-1 levels were
determined by enzyme-linked immunoassay (19).
Studies of vasomotor function in aortic rings. Vasomotor function was
assessed in aortic rings as previously described (6–8). Rings were mounted in an
organ bath containing Krebs Henseleit buffer and equilibrated at a resting ten-
sion of 3 g for 45 min before the experiments. A cumulative dose response to the
constrictor phenylephrine (PE) (1 nmol/L to 10 mmol/L) was ﬁrst performed.
The vascular effect of IGF-1 was assessed by constructing PE dose–response
curves before and 2 h after preincubation with IGF-1 (100 nmol/L) (19). Vaso-
relaxation in response to insulin was assessed by constructing PE dose–
response curves before and after 2 h preincubation with insulin (100 mU/mL).
Relaxation responses to cumulative addition of acetylcholine (1 nmol/L–
10 mmol/L) and sodium nitroprusside (0.1 nmol/L–1 mmol/L) were performed
and responses expressed as percent decrement in preconstricted tension.
Basal NO bioavailability in response to isometric tension was measured by
recording the increase in tension elicited by L-NG-nitro-L-arginine methyl
ester (L-NMMA; 0.1 mmol/L) in aortic segments maximally preconstricted
with PE.
NO synthase activity. Endothelial NO synthase (eNOS) activity was deter-
mined by conversion of [14C]L-arginine to [14C]L-citrulline as we previously
described (19,20). Aortic rings (5 mm in length) or ECs (1 3 106) were in-
cubated at 37°C for 20 min in HEPES buffer, pH 7.4 (in mmol/L): 10 HEPES,
145 NaCl, 5 KCl, 1 MgSO4, 10 glucose, 1.5 CaCl2, containing 0.25% BSA.
0.5 mCi/mL L-[14C]arginine was then added for 5 min and tissues were
stimulated with insulin (100 nmol/L) or IGF-1 (100 nmol/L) for 30 min before
the reaction was stopped with cold PBS, containing 5 mmol/L L-arginine and
4 mmol/L EDTA, after which, tissue was denatured in 95% ethanol. After
evaporation, the soluble cellular components were dissolved in 20 mmol/L
HEPES-Na+ (pH 5.5) and applied to a well equilibrated DOWEX (Na+ form)
column. The L-[14C]citrulline content of the eluate was quantiﬁed by liquid
scintillation counting and normalized against the weight of tissue used or total
cellular protein.
Quantiﬁcation of eNOS, phospho-eNOS, IGF-1R, IR, and hybrids. eNOS,
peNOS, IR, and IGF-1R protein expression was quantiﬁed in aorta and ECs
using Western blotting (19). Immunoprecipitation of protein for the quanti-
ﬁcation of hybrid receptors was achieved by incubating equal amounts of
protein lysates (100 mg) and 50 mL protein A DynaBeads (Invitrogen, Paisley,
U.K.), precoated with indicated anti-rabbit antibodies for 20 min. After three
rounds of washing with PBS–0.01% Tween 20, the beads were resuspended
in 23 Laemmli loading buffer supplied with the NOVEX gel electrophoresis
system. Aortic protein was separated by SDS-PAGE and blots were probed
with mouse anti–IGF-1R-a (for hybrid expression), IR-b (C-19), and IGF-1R-b
(C-20) antibodies for receptor expression (Santa Cruz Biotechnologies, Santa
Cruz, CA).
Cell lysis, immunoblotting, and immunoprecipitation. Primary cells
were lysed in extraction buffer containing (in mmol/L, unless otherwise
speciﬁed) 50 HEPES, 120 NaCl, 1 MgCl2, 1 CaCl2, 10 NaP2O7, 20 NaF, 1 EDTA,
10% glycerol, 1% NP40, 2 sodium orthovanadate, 0.5 mg/mL leupeptin, 0.2
phenylmethylsulfonyl ﬂuoride, and 0.5 mg/mL aprotinin. Cell extracts were
sonicated in an ice bath and centrifuged for 15 min, before protein measure-
ments were carried out by biocinochinic acid assay (Pierce; Thermo Sci-
entiﬁc, Rockford, IL) using the supernatant. Equal amounts of cellular
protein were resolved on SDS-polyacrylamide gels (Invitrogen) and trans-
ferred to polyvinylidine diﬂuoride membranes. Immunoblotting was carried
out with indicated primary antibodies. Blots were incubated with appro-
priate peroxidize-conjugated secondary antibodies and developed with en-
hanced chemiluminescence (Millipore, Billerica, MA). Fifty micrograms of
total cell lysate was used for immunoprecipitation with indicated antibodies:
IRb (C19; Santa Cruz Biotechnology), phophotyrosine (pY4G10; Millipore),
and protein A Dynabeads (Invitrogen), for 20 min at room temperature. Immune
complexes were collected using magnetic ﬁeld, washed extensively with
PBS–0.02% Tween-20, solubilized in Laemmli sample buffer, and analyzed as
above. Immunoblots were scanned on a Kodak (Hemel Hempstead, U.K.)
camera-scanner Image Station 2000R and bands were quantiﬁed using Kodak
ID Image Analysis software.
Gene expression. mRNA was isolated using a commercial kit (Roche, Indi-
anapolis, IN), and the levels of IGF-1R and IR mRNA quantiﬁed using real-time
quantitative PCR (e.g., 6–8).
Mouse pulmonary EC isolation and culture. Primary ECs were isolated
from lungs by immunoselection with CD146 antibody–coated magnetic beads
(Miltenyi Biotech, Surrey, U.K.), as previously reported (21). Sheep anti–rat
IgG magnetic beads were coated with monoclonal rat anti-CD31 antibody
(BD Biosciences, Oxford, U.K.) according to the manufacturer’s instructions.
Lungs were harvested, washed, ﬁnely minced, and digested in Hanks’ balanced
salt solution containing 0.18 units/mL collagenase (10 mg/mL; Roche) for
45 min at 37°C. The digested tissue was ﬁltered through a 70-mm cell strainer
and centrifuged at 1,000 rpm for 10 min. The cell pellet was washed with
DMEM/10% FCS, centrifuged, resuspended in 1 mL DMEM/10% FCS, and
incubated with 1 3 106 CD31 antibody–coated beads at 4°C for 30 min. Bead-
bound cells were separated from non–bead-bound cells using a magnet. Bead-
bound (CD31 positive) and non–bead-bound cells were resuspended in 2 mL
EGM-2-MV (Cambrex, East Rutherford, NJ), supplemented with human epi-
dermal growth factor, hydrocortisone, vascular endothelial growth factor
(VEGF), human ﬁbroblast growth factor-basic, R3-IGF-1, ascorbic acid, genta-
micin, amphotericin-B, and 5% FCS, and plated out. Only the EC population
tested positive for a range of endothelial markers, including eNOS, Tie2, and
CD102 protein, measured using immunoblotting.
siRNA-mediated downregulation of IGF-1R in human umbilical vein
ECs. The following validated oligonucleotides were synthesized from Sigma-
Aldrich (SASI_Hs01_00126194 HUMAN NM_000875). Human umbilical vein
endothelial cells (HUVECs) were grown in endothelial growth medium. Cells
with 70% conﬂuency were transfected with 10 nmol/L siRNA using the NTER
transfection reagent (Sigma-Aldrich) according to the manufacturer’s protocol,
optimized for use in HUVECs by the manufacturer. In brief, a mixture of target
and scrambled siRNA (10 nmol/L), diluted in siRNA buffer and NTER trans-
fection reagent, was preincubated at 37°C for 20 min. Growth medium was
then removed and replaced with culture medium containing the target or
scrambled siRNA mixture and further incubated at 37°C for 4 h. Four hours
post-transfection, the medium was replaced with 0.2% serum containing me-
dium, and HUVECs were incubated overnight. The cells were then stimulated
with 100 nmol/L insulin for 15 min at 37°C, after which the cells were harvested
for protein analysis and Western blotting to analyze phosphorylation levels
of eNOS. Assessment of eNOS activity was carried out on transfected and
serum-starved HUVECs, as described above. After the overnight serum
starvation, the medium was replaced with HEPES buffer, pH 7.4, for 30 min
for equilibration.
Fluorescence-based measurement of NO. Insulin (100 nmol/L)-mediated
NO release was measured as previously described (22). In brief, pulmonary
endothelial cells (PECs) cultured in 96-well plates (90% conﬂuent) in SBS
(in mmol/L: 135 NaCl, 5 KCl, 1.2 MgCl2, 8 glucose, 10 HEPES, and 1.5 CaCl2;
290 mOsm osmolarity; pH 7.4, adjusted using 4 mol/L NaOH) were loaded with
DAF (DAF-FM acetate [Invitrogen, D-23844], stock 5 mmol/L in DMSO; dilute
DAF-FM acetate in SBS 2:1,000 to obtain 10 mmol/L DAF) in SBS by incubating
at room temperature for 45 min. DAF was then removed and cells were washed
in SBS twice. Cells were then left in SBS for 20 min at room temperature. SBS
was replaced again and the plate was loaded into Flex station (FlexStation;
Molecular Devices, Sunnyvale, CA). Fluorescence emission at 520 nm was
measured with 495-nm excitation using the multiwell ﬂuorescence plate reader
system.
Statistics. Results are expressed as mean (SEM). Comparisons within groups
were made using paired Student t tests and between groups using unpaired
Student t tests or repeated-measures ANOVA, as appropriate; where repeated
t tests were performed, a Bonferroni correction was applied. P , 0.05 was
considered statistically signiﬁcant.
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RESULTS
Mice with whole-body haploinsufﬁciency of IGF-1R
are glucose-intolerant but have enhanced insulin-
mediated glucose lowering and increased basal and
insulin-stimulated NO production. IGF-1R+/2 mice had
similar fasting glucose concentrations (5.4 mmol/L [0.3] vs.
4.9 mmol/L [0.1]), and as previously reported, were less
efﬁcient at dealing with a glucose bolus (Fig. 1A), with ex-
aggerated postbolus hyperglycemia compared with wild-
type mice. Despite this glucose intolerance, IGF-1R+/2 mice
had an exaggerated response to insulin, indicative of en-
hanced whole-body insulin sensitivity (Fig. 1B). IGF-1R+/2
mice were resistant to IGF-1–mediated glucose lowering
(Fig. 1C). Fasting plasma insulin and IGF-1 were similar
in IGF-1R+/2 and wild-type mice (Fig. 1D and E). There was no
difference in vascular responses of IGF-1R+/2 and wild-type
mice to acetylcholine or sodium nitroprusside (data not
shown). The vasorelaxant response to IGF-1 in IGF-1R+/2
mice was signiﬁcantly blunted (Fig. 2A and B), and IGF-1–
mediated activation of eNOS, measured using the con-
version of L-arginine to L-citrulline, was also blunted (Fig.
2C), demonstrating that IGF-1–mediated vascular activation
of eNOS is exquisitely sensitive to a reduction in IGF-1R.
Consistent with enhanced basal NO bioavailability, the
constrictor response to the nonspeciﬁc NO synthase inhibitor
L-NMMA was increased in IGF-1R+/2 mice (Fig. 2D–F), and
constrictor responses to PE were blunted in IGF-1R+/2mice
(Fig. 2G and H). To probe the effect of haploinsufﬁciency
of the IGF-1R in ECs, we studied responses in PECs. As
expected, PECs from IGF-1R+/2 mice had substantially
lower expression of IGF-1R (Fig. 2I). We examined the
effect of IGF-1R haploinsufﬁciency on insulin sensitivity
in PECs using a number of approaches. In PECs from IGF-
1R+/2 there was a signiﬁcantly higher level of tyrosine-
phosphorylated IR (Fig. 3A). Consistent with enhanced
insulin sensitivity of PECs from IGF-1R+/2, insulin-stimulated
NO release in PECs from IGF-1R+/2 mice was enhanced
(Fig. 3B). PECs from IGF-1R+/2 mice were also signiﬁ-
cantly more sensitive to insulin-mediated serine phosphor-
ylation of eNOS (Fig. 3C). In aortas from IGF-1R+/2 mice,
there was, as expected, signiﬁcantly less IGF-1R protein
expression than wild-type mice. There was no difference
in IR, but a signiﬁcant reduction in hybrid receptors, in
keeping with an increase in the relative level of free IR
homodimers (Fig. 3D–F).
Mice with EC-speciﬁc deﬁciency of IGF-1R have in-
creased NO production: evidence for a gene dosage
effect. As previously reported, mice homozygous for IGF-
1R deletion were a knockdown model rather than com-
plete deletion (17). “Holoinsufﬁcient”mice, therefore, have
some residual IGF-1R in the endothelium (Supplementary
Fig. 1). EC-speciﬁc IGF-1R–deﬁcient mice had blunting of
IGF-1R–mediated aortic relaxation (Supplementary Fig. 2).
Unlike mice with global IGF-1R deﬁciency, mice with
haploinsufﬁciency and holoinsufﬁciency of the IGF-1R in
the endothelium had similar responses in insulin and glucose
tolerance tests as wild-type mice (Fig. 4A–D), and similar
fasting glucose and insulin concentrations (Fig. 4E and F).
Despite this, and consistent with our ﬁndings in whole-body
IGF-1R+/2 mice, endothelium-speciﬁc IGF-1R+/2 and IGF-
1R2/2 mice had blunted constrictor responses to PE and
an exaggerated constrictor response to L-NMMA, indicative
of increased basal NO bioavailability (Fig. 5A–F). When
comparing wild-type, endothelium-speciﬁc IGF-1R+/2 and
IGF-1R2/2mice, there was a clear gene dose effect on these
vascular responses (Figs. 5G and H). Consistent with our
ﬁndings in mice with whole-body haploinsufﬁciency of the
IGF-1R hybrid receptor, expression was signiﬁcantly lower
in PEC from endothelium-speciﬁc IGF-1R–deﬁcient mice
(Fig. 5I).
FIG. 1. Haploinsufﬁciency of IGF-1R at a whole-body level leads to resistance to IGF-1–mediated glucose lowering and glucose intolerance but
enhanced insulin sensitivity. A: Intraperitoneal glucose tolerance test. B: Intraperitoneal insulin tolerance test. C: Intraperitoneal IGF-1 tolerance
test. Fasting plasma insulin (D) and fasting plasma IGF-1 (E) in mice with haploinsufﬁciency of IGF-1R and wild-type littermates. *P< 0.05; at least
n = 10 per group for all experiments. Data shown as mean 6 SEM.
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Restoring insulin-mediated endothelial responses
in mice with whole-body haploinsufﬁciency of IR by
reducing IGF-1R. We have previously demonstrated that
IR+/2 mice, while maintaining glucose competence, have
signiﬁcant blunting of insulin-mediated vasorelaxation and
eNOS activation (6,20). To test our hypothesis that changing
IR:IGF-1R stoichiometry would impact favorably on insulin-
mediated NO production in vivo, we generated mice
with whole-body haploinsufﬁciency of the IR and IGF-1R.
IGF-1R+/2/IR+/2 and IR+/2 mice had similar fasting glucose
concentrations and responses to a glucose bolus (Fig. 6A).
IGF-1R+/2/IR+/2 mice had higher fasting glucose concen-
trations than IGF-1R+/2 and wild-type mice (Supplementary
Fig. 3A). In insulin tolerance tests, IGF-1R+/2/IR+/2 and IR+/2
mice had similar responses (Fig. 6B and Supplementary Fig.
3B). IGF-1R+/2/IR+/2 mice had increased insulin-stimulated
eNOS activation in aortic rings (Fig. 6C), restored aortic
relaxation in response to insulin (Fig. 6D–F), and increased
NO generation in PEC in response to insulin (Fig. 6G andH),
and reduced numbers of hybrid receptors (Fig. 6I).
Reducing IGF-1R in ECs enhances basal and insulin-
stimulated eNOS phosphorylation. To examine the
speciﬁc effects of reducing IGF-1R expression on basal
serine phosphorylation and activation of eNOS in response
to insulin, we used siRNA-mediated knockdown of IGF-1R.
siRNA-treated HUVEC had a signiﬁcant reduction in IGF-1R
but no change in IR (Fig. 7A–C), assessed using RT-PCR.
This reduction in IGF-1R led to a signiﬁcant decrease in
hybrid receptors (Fig. 7D). In keeping with our in vivo
ﬁndings, knocking down IGF-1R led to an increase in
basal and insulin-stimulated serine-phosphorylated eNOS
(Fig. 7E), and increased insulin-mediated eNOS acti-
vation (Fig. 7F).
DISCUSSION
The present report using a comprehensive in vivo and in
vitro approach describes a novel mechanism by which the
bioavailability of the endothelium-derived signaling radical
NO is regulated. We have demonstrated using mice with
FIG. 2. Haploinsufﬁciency of IGF-1R at a whole-body level leads to resistance to IGF-1–mediated aortic relaxation, blunted constriction to PE, and
enhanced basal aortic NO production. Endothelial function in aortic rings from mice with haploinsufﬁciency of IGF-1R and wild-type littermates.
A: Vasorelaxation in response to IGF-1 in wild type. B: IGF-1 relaxation is blunted in IGF-1R–deﬁcient mice. C: eNOS activity in response to IGF-1
is blunted in IGF-1R haploinsufﬁcient mice. D and E: Constriction in response to L-NMMA in wild-type mice (D) and IGF-1R haploinsufﬁcient mice
(E). F: Maximal constriction (Emax) in response to L-NMMA indicative of NO bioavailability is signiﬁcantly higher in IGF-1R haploinsufﬁcient
mice. G: Constriction dose–response curve to PE in wild-type and IGF-1R haploinsufﬁcient mice. H: Maximal constriction in response to PE is
reduced in mice with haploinsufﬁciency of IGF-1R. I: IGF-1R expression in isolated pulmonary ECs in mice with haploinsufﬁciency of IGF-1R and
wild-type littermates. *P < 0.05; at least n = 10 per group for all experiments.
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whole-body haploinsufﬁciency of IGF-1R and endothelium-
speciﬁc deletion of IGF-1R that NO bioavailability is neg-
atively regulated by IGF-1R in the endothelium.
To examine the therapeutic potential of manipulating
IGF-1R numbers, we generated mice with whole-body
haploinsufﬁciency of the IR and IGF-1R. We have previously
demonstrated substantial abnormalities of EC function in
IR+/2 mice (6,7,20). Reducing IGF-1R numbers in IR+/2
mice restored insulin-mediated vasorelaxation, enhanced
insulin-stimulated eNOS activation, and enhanced insulin-
stimulated NO release in ECs. In vitro experiments in
human ECs conﬁrmed that IGF-1R deletion enhances basal
and insulin-stimulated serine phosphorylation of eNOS and
eNOS activity in response to insulin. These data demon-
strate for the ﬁrst time that IGF-1R is a key negative reg-
ulator of insulin sensitivity and NO bioavailability in the
endothelium.
Insulin resistance, endothelial NO synthase, and ath-
erosclerosis. A well deﬁned series of steps occur in the
arterial wall during the development of atherosclerosis (23).
Early in the development of atherosclerosis, before the
onset of morphological changes, there are important alter-
ations in EC phenotype, a situation described as endothelial
dysfunction. A key feature of endothelial dysfunction is
a reduction in NO bioavailability (24). In the endothelium,
NO is generated by L-arginine to L-citrulline conversion
principally by the NO synthase isoform eNOS (for review
see Ref. 25). NO can inﬂuence multiple steps in the ath-
erosclerotic process, including vascular smooth muscle
cell phenotype (26), vascular inﬂammation (27), platelet
aggregation (28), EC migration, proliferation and survival
(29), and progenitor cell mobilization (30). In addition, NO
has physiologically important antioxidant actions (31).
eNOS activity is regulated at multiple different levels
(for review see 25), including the availability of its sub-
strate or cofactors, protein–protein interactions, post-
translational modiﬁcations, and serine phosphorylation.
Serine phosphorylation of eNOS accelerates the rate of
electron ﬂow through the enzyme, increases its calcium
sensitivity, and augments NO biosynthesis and release (32).
Insulin and IGF-1, via activation of their receptors, have
been shown to increase levels of serine-phosphorylated
eNOS in vivo (19), and in vitro (33), and to stimulate NO
production (34). In humans, insulin sensitivity closely corre-
lates with NO bioavailability in resistance vessels (35,36).
In a novel murine model of endothelium-speciﬁc insulin
FIG. 3. Haploinsufﬁciency of IGF-1R at a whole-body level leads to increased levels of tyrosine-phosphorylated IR, increased insulin-mediated NO
production, and serine phosphorylation of eNOS in ECs. A: Enhanced basal tyrosine phosphorylation of IR in isolated ECs from IGF-1R hap-
loinsufﬁcient mice. B: Increased insulin-mediated NO production in ECs from IGF-1R haploinsufﬁcient mice (bottom panel shows representative
time series graph for change of DAF-FM ﬂuorescence in pulmonary ECs in response to insulin [100 nmol/L]). C: Serine phosphorylation of eNOS
is enhanced in response to insulin in ECs from IGF-1R haploinsufﬁcient mice. D: No difference in IR levels in ECs from IGF-1R haploinsufﬁcient
mice. E: Reduced IGF-1R levels in ECs from IGF-1R haploinsufﬁcient mice. F: Reduced hybrid receptors in ECs from IGF-1R haploinsufﬁcient mice.
*P< 0.05; n = 5–10 mice per experiment. AU, arbitrary unit; IB, immunoblotted; WT, wild type. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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resistance, we demonstrated a signiﬁcant reduction in
insulin-mediated eNOS phosphorylation and NO bio-
availability (8). In other preclinical models, eNOS phos-
phorylation status has been shown to play an important
and favorable role in a range of pathological situations
reminiscent of human vascular disease such as stroke
(37) and lower limb ischemia (38).
NO bioavailability in mice with whole-body haploin-
sufﬁciency of IGF-1R. In this mouse, previously shown to
be protected against oxidative stress (16), and age-related
inﬂammatory degenerative brain disease (39), we demon-
strated an intriguing phenotype. Using a range of comple-
mentary approaches we showed that despite whole-body
glucose intolerance, haploinsufﬁciency of IGF-1R leads
to the favorable vascular phenotype of reduced vasco-
constriction to PE, increased basal NO production, and
increased EC insulin sensitivity leading to augmented
insulin-mediated NO generation.
IGF-1R+/2mice are glucose intolerant after a glucose
bolus but have a greater fall in plasma glucose in response
to a systemic bolus of insulin. The present report and
studies in mice with pancreatic b cell–speciﬁc deletion of
IGF-1R help explain this apparently divergent metabolic
phenotype. Mice with pancreatic b cell–speciﬁc deletion of
IGF-1R are thought to have impaired insulin secretion/
glucose sensing (40), accounting for the abnormal glucose
tolerance. Our dataset provide an explanation for the
increased insulin sensitivity, i.e., removal of the negative
regulatory effect of IGF-1R on signaling through IR.
Mice with endothelium-speciﬁc reduction of IGF-1R.
To separate the systemic effects of IGF-1R from the EC
effects, we generated mice with different levels of IGF-1R
using the Tie-2 promoter to direct gene expression princi-
pally to the endothelium. Mice with Tie-2–directed deletion
of IGF-1R had glucose and insulin tolerance tests similar to
wild-type mice, but reduced aortic constriction to PE and
increased basal NO. Consistent with a role for IGF-1R
numbers as the principal mechanism underlying this ob-
servation, we demonstrated a gene dose effect of IGF-1R
on PE-induced constriction and basal NO production.
IGF-1R:IR stoichiometry and insulin sensitivity. It is
well established that IR and IGF-1R can heterodimerize to
form insulin-resistant hybrid receptors (10–14). The forma-
tion of hybrid receptors is determined by the molar pro-
portion of receptors. In ECs, the speciﬁc binding of insulin
is signiﬁcantly lower than IGF-1, indicative of a lower number
of homodimeric IR than IGF-1R (41); studies suggest that
IGF-1R outnumber IR tenfold (34). Crucially, for high-afﬁnity
binding of insulin to the IR and activation to occur, binding
to both subunits is necessary, whereas IGF-1 requires only
one subunit (13). This provides one explanation as to why
hybrids have a low afﬁnity for insulin but bind IGF-1 with
the same high afﬁnity as IGF-1R homodimers. In vitro studies
of a range of cell types (42–45) have suggested that reduction
FIG. 4. Metabolic proﬁles of mice with haploinsufﬁciency and holoinsufﬁciency of IGF-1R in the endothelium. A and B: Glucose tolerance tests (A)
and insulin tolerance tests (B) are similar in wild type and mice with haploinsufﬁciency of IGF-1R in the endothelium. C and D: Glucose tolerance
tests (C) and insulin tolerance tests (D) are similar in wild type and mice with holoinsufﬁciency of IGF-1R in the endothelium. E and F: Fasting
blood glucose (E) and fasting insulin levels (F) are similar in wild-type mice and mice with haploinsufﬁciency and holoinsufﬁciency of IGF-1R in
the endothelium. At least n = 4 mice per group for all experiments. (A high-quality color representation of this ﬁgure is available in the online
issue.)
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of IGF-1R density enhances insulin sensitivity. In cells from
humans with polymorphisms that lead to a reduction in
IGF-1R density, a similar pattern of enhanced insulin sen-
sitivity has been demonstrated (46).
Reducing IGF-1R numbers in vivo to restore vascular
function in a model of insulin resistance–related vas-
cular disease: proof of concept. Insulin-resistant hu-
mans have a signiﬁcant reduction in cell surface IR (14) and
reduced insulin-mediated, NO–dependent vasorelaxation
(47). We have previously used mice with whole-body
haploinsufﬁciency of the IR as a model of non-obese
whole-body insulin resistance. These mice, similar to
insulin-resistant humans, have reduced insulin-mediated
eNOS phosphorylation, reduced insulin-mediated eNOS ac-
tivation, and reduced insulin-mediated vasorelaxation (6,7).
More recently, consistent with reduced NO bioavailability,
we have shown that these mice have reduced endothelial
progenitor cell mobilization in response to VEGF and
delayed endothelium regeneration after femoral artery
wire injury (20). To examine whether reducing IGF-1R in
IR+/2 mice can restore insulin-mediated NO production,
we generated IGF-1R+/2/IR+/2 mice. IGF-1R+/2/IR+/2 mice
had enhanced insulin-mediated NO release in PEC and en-
hanced insulin-mediated vasorelaxation and eNOS activa-
tion in aortas compared with IR+/2. In complementary
studies in HUVECs, we knocked down IGF-1R. HUVEC
FIG. 5. Vascular responses in aortic rings of mice with haploinsufﬁciency and holoinsufﬁciency of IGF-1R in the endothelium. A: Constrictor
responses to PE in rings preincubated with L-NMMA in wild-type mice. B: Enhanced constrictor responses to PE in mice with EC-speciﬁc hap-
loinsufﬁciency of IGF-1R. C: Constrictor responses to PE in rings preincubated with L-NMMA in wild-type mice. D: Enhanced constrictor responses
(indicative of increased NO bioavailability) in rings in mice with EC-speciﬁc holoinsufﬁciency of IGF-1R. E: Blunted constrictor responses to PE in
mice with EC-speciﬁc haploinsufﬁciency of IGF-1R. F: Blunted constrictor responses to PE in mice with EC-speciﬁc holoinsufﬁciency of IGF-1R.
G: Maximal change in tension in response to L-NMMA in wild-type mice, mice with EC-speciﬁc haploinsufﬁciency of IGF-1R, and mice with EC-speciﬁc
holoinsufﬁciency of IGF-1R, demonstrating gene dose effect of IGF-1R on NO bioavailability. H: Maximal change in tension in response to PE in
wild-type mice, mice with EC-speciﬁc haploinsufﬁciency of IGF-1R, and mice with EC-speciﬁc holoinsufﬁciency of IGF-1R, demonstrating gene
dose effect of IGF-1R on constrictor responses to PE. I: Quantiﬁcation of hybrid receptors in wild-type mice, mice with EC-speciﬁc hap-
loinsufﬁciency of IGF-1R, and mice with EC-speciﬁc holoinsufﬁciency of IGF-1R. All experiments had at least n = 5 mice. *P< 0.05. (A high-quality
color representation of this ﬁgure is available in the online issue.)
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deﬁciency in IGF-1R, in keeping with our ﬁndings in vivo, had
increased basal serine-phosphorylated eNOS and enhanced
insulin-mediated serine eNOS phosphorylation and ac-
tivation.
Potential mechanisms linking hybrid formation and
type 2 diabetes. An increase in hybrid receptors is
a hallmark of type 2 diabetes and obesity (14,48,49). Ele-
gant studies from Sesti et al. provide important insights
into how aspects of the type 2 diabetes phenotype may
regulate the formation of hybrids. In a study of patients
with primary, nongenetically determined hyperinsulinaemia
(i.e., patients with insulinoma), Federici et al. (50) dem-
onstrated that insulin-mediated downregulation of the IR,
by shifting IR:IGF-1R stoichiometry in favor of IGF-1R led
to a higher proportion of hybrid receptors in skeletal
muscle in these patients. This suggests that hybrid re-
ceptor formation in patients with type 2 diabetes may be
driven by changes in insulin concentration.
The role of hyperglycemia was also examined by this
group (51). In diabetic rats rendered normoglycemic,
Federici et al. showed that reducing glucose reduced hybrid
receptor numbers. Moreover, the glucosamine pathway, at
least in part, may mediate glucose-induced formation of
hybrid receptors. These studies demonstrate that by driving
the formation of hybrid receptors, different components of
the type 2 diabetes phenotype may initiate a vicious cycle,
leading to worsening of insulin sensitivity.
In summary we have demonstrated in complementary in
vivo and in vitro models that IGF-1R is an important neg-
ative regulator of insulin sensitivity in the endothelium.
Deletion of IGF-1R leads to a potentially favorable increase
in NO bioavailability and, in a well characterized model of
human insulin resistance, rescues the adverse phenotype.
Our dataset raises the exciting possibility that IGF-1R may
be a novel target for the treatment of insulin resistance–
related vascular disease.
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